ionBottles Research Library
All studies indexed via PubMed®
Last updated: May 18, 2026
Peer-Reviewed Research

Top Clinical Studies on Molecular Hydrogen

Molecular hydrogen has been the subject of 1,300+ peer-reviewed papers since the seminal 2007 Nature Medicine publication. The studies below are among the most clinically relevant and most-cited in the field. Each is linked to its original abstract on PubMed.

1,300+
Peer-reviewed studies
Since 2007
Of active research
170+
Disease models studied
2,000+
Citations on foundational paper
Methodology RCT Pilot Study Review Observational
Review Foundation

Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals

Ohsawa I, Ishikawa M, Takahashi K, et al.

Nature Medicine · 2007 · PMID: 17486089

The foundational paper for the entire field. Showed H₂ selectively reduces hydroxyl radicals (•OH) and peroxynitrite — the most cytotoxic species in cellular oxidative stress — while leaving beneficial reactive oxygen species intact. Cited 2,000+ times in the subsequent literature.

In vitro + animal model (rat middle cerebral artery occlusion)

Read full abstract on PubMed →
2007
Review Foundation

Recent progress toward hydrogen medicine: potential of molecular hydrogen for preventive and therapeutic applications

Ohta S.

Current Pharmaceutical Design · 2011 · PMID: 21219114

Comprehensive mechanism review establishing molecular hydrogen as a non-classical antioxidant with disease-modifying potential across multiple inflammatory and metabolic conditions. Surveys the early human and animal evidence and outlines the proposed selective-radical-scavenging mechanism.

Read full abstract on PubMed →
2011
Review Inflammation

Beneficial biological effects and the underlying mechanisms of molecular hydrogen — comprehensive review of 321 original articles

Ichihara M, Sobue S, Ito M, et al.

Medical Gas Research · 2015 · PMID: 31958022

Systematic review covering 170+ disease models — including inflammatory, metabolic, neurological, and oxidative-stress conditions — where molecular hydrogen has been investigated for preventive and therapeutic effects. Discusses delivery routes, dosing, and mechanism-of-action evidence to date.

Read full abstract on PubMed →
2015
Pilot Study Type-2 Diabetes

Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance

Kajiyama S, Hasegawa G, Asano M, et al.

Nutrition Research · 2008 · PMID: 18707463

Randomized, double-blind, placebo-controlled crossover pilot. 30 patients with type-2 diabetes or impaired glucose tolerance drank 900 mL of hydrogen-rich water daily for 8 weeks. Researchers observed changes in oxidative-stress markers, lipid profile, and adiponectin levels in the hydrogen arm versus placebo.

N=30 · 8-week crossover · double-blind, placebo-controlled

Read full abstract on PubMed →
2008
Pilot Study Arthritis

Consumption of water containing a high concentration of molecular hydrogen reduces oxidative stress and disease activity in patients with rheumatoid arthritis

Ishibashi T, Sato B, Rikitake M, et al.

Medical Gas Research · 2012 · PMID: 22520831

Open-label pilot study of 20 patients with rheumatoid arthritis drinking high-concentration hydrogen water (4–5 ppm, 530 mL/day) for 4 weeks. Researchers observed changes in oxidative-stress markers (8-OHdG) and reported disease-activity scores (DAS28) over the intervention period.

N=20 · 4-week pilot · open-label

Read full abstract on PubMed →
2012
Observational Cardiovascular

Consumption of water containing over 3.5 mg of dissolved hydrogen could improve vascular endothelial function

Sakai T, Sato B, Hara K, et al.

Vascular Health and Risk Management · 2014 · PMID: 25378931

Open-label trial in 34 adults assessing flow-mediated dilation (FMD) of the brachial artery before and after drinking high-concentration hydrogen water. Researchers reported changes in endothelial function — a surrogate marker linked to long-term cardiovascular health.

N=34 · open-label

Read full abstract on PubMed →
2014
RCT Brain & Neurological

Pilot study of H₂ therapy in Parkinson’s disease: a randomized double-blind placebo-controlled trial

Yoritaka A, Takanashi M, Hirayama M, et al.

Movement Disorders · 2013 · PMID: 23400965

48-week randomized, double-blind, placebo-controlled pilot in levodopa-treated Parkinson’s patients drinking 1,000 mL/day of hydrogen-rich water. Researchers tracked Unified Parkinson’s Disease Rating Scale (UPDRS) scores between the hydrogen and placebo arms.

N=17 · 48 weeks · randomized, double-blind, placebo-controlled

Read full abstract on PubMed →
2013
RCT Recovery

Hydrogen-rich water consumption positively affects muscle performance, lactate response, and alleviates delayed-onset muscle soreness after resistance training

Botek M, Krejčí J, McKune AJ, Sládecčková B.

Journal of Strength and Conditioning Research · 2022 · PMID: 33555824

Randomized, double-blind, placebo-controlled crossover trial in resistance-trained men. Participants consumed hydrogen-rich water before exercise; researchers measured blood lactate, countermovement-jump performance, and delayed-onset muscle soreness (DOMS) ratings versus placebo.

N=12 · crossover · randomized, double-blind, placebo-controlled

Read full abstract on PubMed →
2022
Pilot Study Inflammation

Hydrogen-rich water reduces liver fat accumulation and improves liver enzyme profiles in patients with non-alcoholic fatty liver disease: a randomized controlled pilot trial

Korovljev D, Stajer V, Javorac D, Ostojić SM.

Irish Journal of Medical Science · 2019 · PMID: 30982748

28-day randomized controlled pilot trial in overweight outpatients with non-alcoholic fatty liver disease drinking 1 L/day of hydrogen-rich water versus placebo. Researchers used dual-echo MRI to assess liver fat and measured liver enzyme (AST/ALT) profiles before and after the intervention.

N=12 · 28-day pilot · randomized, controlled

Read full abstract on PubMed →
2019
RCT Type-2 Diabetes

The effects of 24-week, high-concentration hydrogen-rich water on body composition, blood lipid profiles, and inflammation biomarkers in adults with metabolic syndrome

LeBaron TW, Singh RB, Fatima G, et al.

Diabetes, Metabolic Syndrome and Obesity · 2020 · PMID: 32273740

Randomized, double-blind, placebo-controlled trial in adults with metabolic syndrome. Over 24 weeks, researchers tracked body composition, blood lipids, HbA1c, glucose, and inflammation biomarkers between the hydrogen and placebo arms.

N=60 · 24 weeks · randomized, double-blind, placebo-controlled

Read full abstract on PubMed →
2020

Editorial Note

This page is maintained as a public reference for the molecular-hydrogen research literature. Inclusion does not constitute endorsement, and study findings cited above describe outcomes observed in controlled clinical settings — they may not reflect outcomes in typical use. ionBottles products are not intended to diagnose, treat, cure, or prevent any disease. This is not medical advice. Consult your healthcare provider for guidance specific to your situation.